NovaBridge, Visara announce results from VIS-101 Phase 2a Wet AMD study

NovaBridge (NBP) Biosciences, a global biotechnology platform company committed to accelerating access to innovative medicines, and its subsidiary, Visara announced topline results from the Phase 2a study of VIS-101. VIS-101 produced rapid and robust efficacy, and durable treatment responses with both 3 mg and 6 mg dose cohorts: Mean improvement in Best Corrected Visual Acuity of greater than10 Early Treatment of Diabetic Retinopathy Study letters; Median central subfield thickness reduction of 100-150 mm; Potential best-in-class durability with: two thirds of patients retreatment-free at 4 months, half of patients retreatment-free at 6 months; Favorable safety and no dose limited toxicity